Real-World Data Is Reshaping How We Supply Clinical Trials — And It's About Time

By Zizi Imatorbhebhe, MBA, MS, PMP, chief growth officer at Bios Health Group

For anyone who has spent time in clinical development, the supply chain headaches are familiar. You over-manufacture because you don't know exactly who will enroll, or when. You scramble when eligibility criteria turn out to be narrower than anticipated. You watch expensive investigational product sit in a depot while sites wait for patients who fit a protocol designed without enough real-world insight.

It doesn't have to be this way. And increasingly, it isn't.

With over 20 years in life sciences — spanning clinical development, business development, strategic partnerships, and commercialization — I've watched real-world data go from a buzzword to a genuine operational lever. And a landmark study released just this month by the Tufts Center for the Study of Drug Development (Tufts CSDD), sponsored by Verana Health, confirms what many of us have been sensing: RWD and RWE have evolved from being supplemental tools to strategic game-changers embedded across the entire drug development life cycle.¹

For clinical supply specifically, that shift is enormous.

Getting Forecasting Right From The Start

Clinical supply planning lives and dies by forecasting accuracy. And forecasting accuracy lives and dies by how well you understand your patient population before the trial begins. Historically, that understanding came from investigators' intuitions, past trials, and a lot of hopeful assumptions. Real-world data changes that equation fundamentally.

The Tufts CSDD study, which drew on interviews with leaders from 18 pharmaceutical, biotech, and CRO organizations across oncology, neurology, ophthalmology, dermatology, and urology, found that RWD is now being used to sharpen trial feasibility assessments and refine patient eligibility criteria before a single site is activated.² That means supply teams can build forecasts grounded in actual patient prevalence, treatment patterns, and site-level prescribing behavior — not just protocol assumptions.

The downstream effect? Less waste, leaner buffers, and more confident manufacturing decisions. For clinical supply teams, this translates directly into more precise demand forecasting, better alignment of manufacturing runs, and reduced reliance on costly overages built to hedge against uncertainty.

Smarter Trial Design Means Smarter Supply Strategy

One of the most significant supply implications of RWD adoption is the growing use of hybrid trial designs and external control arms. When you remove the need to randomize patients to a standard-of-care comparator — because that comparator data already exists in the real world — you fundamentally change the supply picture. Fewer arms to supply. Fewer depots to manage. Fewer patients exposed to unnecessary treatment just to satisfy a control arm requirement.

In one notable example, RWE contributed to a 40% reduction in planned sample size for a pivotal Phase 3 program, translating to six months of saved development time. ³ For supply chain teams, that kind of reduction isn't just a timeline win — it's a significant reduction in manufacturing volume, cold chain logistics, and expiry risk. From a supply perspective, this also simplifies packaging configurations, reduces the number of SKUs required, and streamlines depot and distribution strategies across regions.

Speed Where It Matters Most

Participating companies in the Tufts CSDD study reported that rapid access to RWD enables faster decision-making, reduces trial burden, and accelerates response times when regulators come back with questions.² That last point is underappreciated from a supply perspective. Regulatory back and forth can freeze supply chains in limbo — holding product in depots, delaying destruction decisions, and creating costly uncertainty. Anything that shortens that cycle has direct supply chain value. For supply teams, faster decision-making can mean earlier release or reallocation of inventory, reduced depot dwell time, and fewer delays tied to regulatory uncertainty.

RWD Is Driving Measurable Supply Efficiency

Ten of the 14 companies surveyed in the Tufts study anticipate a measurable increase in ROI from RWD investment within the next one to two years.² That's not a future promise — that's organizations already seeing the returns and doubling down.

As someone who has sat at the intersection of clinical strategy and operations for two decades, I find this genuinely exciting. We have spent years trying to make clinical supply chains more adaptive, more precise, and less wasteful. Real-world data is finally giving us the upstream intelligence to do that properly.

The trials of the future won't just be smarter scientifically. They'll be leaner operationally. And for everyone responsible for getting the right product to the right patient at the right time, that matters enormously. As adoption grows, clinical supply organizations need to integrate RWD insights more directly into planning systems, from IRT configuration to ongoing inventory optimization.

References:

1. Tufts Center for the Study of Drug Development. (2026). The Use of Real-World Data and Evidence on Clinical Trials(sponsored by Verana Health). April 7, 2026.
2. New Study Shows Increasing Value of Real-World Data (RWD) in Clinical Trials
3. The inclusion of real world evidence in clinical development planning

About The Author:

Zizi Uzezi Imatorbhebhe, MBA, MS, PMP, is chief growth officer at Bios Health Group, partnering with biotech and life sciences companies to navigate clinical development and commercialization. With 20+ years across pharmaceuticals, biotech, and CROs, she advances programs from early development to market readiness. Zizi works with global teams to shape target product profiles, align risk-adjusted integrated development plans, and leverage real-world evidence to turn insights into actionable strategies. She also advises CEOs and founders on capital and investment. Actively engaged in the Bios Innovation Circle, Zizi focuses on innovative approaches to optimize trial design, improve efficiency, and enhance patient impact. She can be reached at solutions@bioshealthgroup.com.